Xadcera Biopharmaceutical (suzhou) Co., Ltd.

This is the first human study of an experimental cancer drug called DM002 for people with advanced solid tumors including ovarian, prostate, endometrial, and colorectal cancers. The study has two parts: first finding the safest dose, then testing that dose to see how well it work…